Tagrisso prolongs progression free survival in resectable EGFR patients.

[Denzie]

Okay, I’m science fan geeking out this week. The American Society of Clinical Oncology (ASCO) is holding their annual conference virtually. This paper comes out of that conference.

asco.org/about-asco/press-c...

[JeanE41]

This is exciting news.

[Beepers7]

Hi Denzil,

Thanks so much for the latest trial information from ASCO on Osimertinib. As I’ve just finished a round of chemo post wedge section surgery and have EGFR exon19 mutation it sounds exciting. I mentioned Tagrisso to my oncologist a few weeks ago and she said they(KP) only for stage 4. I’m stage 3a.

Hopefully that will change after results of this study.

Thanks so much, SteveO

[Beepers7 in reply to Beepers7]

Denzie 😇

Sorry about misspelling your name😊

[Denzie Moderator Volunteer in reply to Beepers7]

So glad it was of interest to you, Steve. When is your next appointment? Print the abstract out and take it along to your next appointment. It’s one way to let your doctor know that you intend to be a full partner in your care.

[Beepers7 in reply to Denzie]

HI Denzie,

I have a second course of adjuvant chemo 6/9 (3 days ) then followup appointment with oncologist. Seems there are two separate studies recently released for Tagrisso, ADADURA and ACHEMIST.

Is that correct? Thanks for all your information. SteveO

[Denzie Moderator Volunteer in reply to Beepers7]

Yes! And curiosity compelled me to see how many active and recruiting Osimertinib trials there are. There are 34 active not recruiting and 50 recruiting. We need to keep these things funded!

clinicaltrials.gov/ct2/resu...

[Beepers7 in reply to Denzie]

I never imagined there would be so many trials. What can we do to keep them funded?